Ascendancy Healthcare, Inc. dedicated to the commercialization of therapeutic products to meet unmet medical needs in China and other high-growth Asian markets, announced today a multi-year collaboration with Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services. Under the terms of the agreement, Quintiles will provide product assessments, clinical research services, including trial planning, productivity optimization, and execution of cost-efficient studies, for therapeutic compounds Ascendancy in-licenses for development and commercialization in China and other Asian markets.
“We are delighted to announce our new relationship with Quintiles, which has a leading presence as a CRO in China, with full capabilities to support drug development in Chinaâ€
The agreement will span a full spectrum of clinical development activities necessary for the registration of products for commercialization in China. The collaboration will be overseen by a joint development committee composed of representatives from both organizations. The agreement lasts for two and one-half years, with an option for both organizations to renew for an additional two and one-half year period. Further terms of the agreement, including financial details, are not being disclosed.